North China Pharma To Appeal $162 Million Antitrust Fine By U.S.
This article was originally published in PharmAsia News
North China Pharmaceutical Group, the first Chinese pharmaceutical company to be fined for antitrust violations in the U.S., said it would appeal the $162 million fine in a federal court.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"